American Trust Neurocrine Biosciences Inc Transaction History

American Trust

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 21, 2024	SELL	$106.07 - $132.76 $39,245 - $49,121	-370 Reduced 12.13%	2,680 $353,000
Q3 2023 Nov 15, 2023	SELL	$94.02 - $117.1 $70,515 - $87,825	-750 Reduced 19.74%	3,050 $343,000
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $10,743 - $12,584	-120 Reduced 3.06%	3,800 $358,000
Q1 2023 May 22, 2023	SELL	$94.11 - $123.02 $245,627 - $321,082	-2,610 Reduced 39.97%	3,920 $396,000
Q4 2022 Feb 16, 2023	BUY	$106.72 - $127.06 $696,881 - $829,701	6,530 New	6,530 $779,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of American Trust, based on Form 13F filings with the SEC.

Stay updated on American Trust with notifications on news.